Infectious Disease CRISPR Market

Infectious Disease CRISPR Market Analysis

The Infectious Disease CRISPR Market size is estimated at USD 295.80 million in 2025, and is expected to reach USD 751.70 million by 2030, at a CAGR of 20.34% during the forecast period (2025-2030).

Various factors drive the growth of the infectious disease CRISPR market, such as the rising prevalence of infectious diseases, advancements in CRISPR technology, and increasing investment in biotechnology and genomics.

The increasing prevalence of infectious diseases, such as influenza, cholera and human immunodeficiency virus (HIV), among others, is expected to boost the demands for advanced diagnostics and therapeutic tools like CRISPR technology, thus fueling market growth. For instance, a study published in the Zoonoses Joural in May 2024 mentioned that the highest number of influenza cases, totaling 98.9 thousand, were found in the United States, followed by Canada and Australia with 19.3 thousand and 19.1 thousand cases, respectively, between January and March 2024. Additionally, the same source reported that the onset of the high cholera season has led to a dramatic increase in cases across all regions, with reported cases reaching 23.9 thousand in Afghanistan, 18.1 thousand in Zambia, and 14.0 thousand in Zimbabwe between January and March 2024. Thus, the increasing number of infectious diseases worldwide is anticipated to drive the need for advanced CRISPR technology in diagnosis and therapeutics, boosting the market growth of infectious disease CRISPR over the forecast period.

Moreover, significant advancements in CRISPR-Cas systems, including improved specificity and efficiency, facilitate broader acceptance of infectious diseases. For instance, an article published in the Journal of Diagnostics (Basel) in July 2023 mentioned that CRISPR/Cas12 and CRISPR/Cas13 offer fast, sensitive, specific, portable, and cost-effective approaches for diagnosing bacterial and viral infections and thus can be used as point-of-care testing (POCT). These CRISPR-based diagnostic techniques rely on type V CRISPR/Cas12, commonly referred to as DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR), or type VI CRISPR/Cas13, known as Specific High-sensitive Enzymatic Reporter UnLOCKing (SHERLOCK). Additionally, in June 2024, researchers at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard and Princeton University developed an accurate, affordable, and rapid paper strip test. This test utilizes CRISPR technology to differentiate between the two primary types of seasonal flu, influenza A and B, and the seasonal flu subtypes H1N1 and H3N2, enabling more patients to identify their specific flu type and receive appropriate treatment. Thus, such advancements in CRISPR-based technology are anticipated to be widely adopted by patients and healthcare professionals and are expected to fuel market growth.

Hence, the increasing prevalence of infectious diseases and advancements in CRISPR technology drive market growth. However, ethical concerns and regulatory challenges may impede the market growth of infectious disease CRISPR over the forecast period.

Infectious Disease CRISPR Market Trends

The Diagnostics Segment is Anticipated to Witness a Largest Share in the Infectious Disease CRISPR Market Over the Forecast Period

CRISPR technology is revolutionizing diagnostics due to its accuracy, rapidity, and capability to identify specific genetic sequences for diagnosing infectious diseases caused by viruses, bacteria, and other pathogens. Thus, due to its advantages in diagnosing infectious diseases, CRISPR technology is likely to contribute to the segment's growth over the forecast period.

The rising advancements in CRISPR technology make it efficient in diagnosing various infectious diseases such as COVID-19 and tuberculosis, among others, thus leading to its wider adoption and boosting segment growth. For instance, in a study published in Nature Communications in March 2024, CRISPR-based tests can identify SARS-CoV-2, as well as a harmful bacterium and cancer mutations, with sensitivity comparable to a polymerase chain reaction (PCR), without needing a preamplification step, thus making it more suitable for point-of-care systems. This innovative approach could lead to more affordable test-kit components, including lateral flow strips similar to those used in rapid COVID tests. Additionally, in August 2024, the Indian Council of Medical Research developed a cost-effective tuberculosis (TB) testing technology to detect the disease using a patient's sputum in Assam, India. The 'CRISPR case-based TB detection system' is lightweight, portable, and consists of three testing steps. Thus, such advancements and advantages of CRISPR technology are anticipated to boost its adoption and thus propel the segment growth.

Rising government support for market players advancing CRISPR-based diagnostics in infectious diseases is anticipated to drive the segment's growth. For instance, in September 2023, Sherlock Biosciences secured additional funding from the Bill & Melinda Gates Foundation to enhance the development of rapid, instrument-free molecular diagnostics by leveraging CRISPR technology for Human Papillomavirus (HPV), which empowered the company to fulfill its mission of providing cutting-edge diagnostic technologies to the most remote and underserved areas. Thus, such initiatives are expected to drive the segment growth over the study period.

Thus, owing to the above-mentioned factors, such as the rising advancements in CRISPR-based diagnostics for infectious diseases and increasing government initiatives, the segment growth is expected to continue.

North America is Expected to Occupy the Largest Share in the Infectious Disease CRISPR Market Over the Forecast Period

The expansion of the infectious disease CRISPR market in North America is fueled by various factors such as technological advancements, rising incidence of infectious diseases, and the region’s emphasis on innovative research with funding.

The strong research and development environment promotes the advancement of novel CRISPR-based diagnostics and treatments for infectious diseases, thus anticipated to drive the market growth of infectious disease CRISPR in the region. For instance, in March 2024, the researchers at the ADA Forsyth Institute in the United States adopted the innovative CRISPR-Cas-based diagnostic platform known as Specific High-Sensitivity Enzymatic Reporter Unlocking (SHERLOCK) for developing an affordable and quick detection method designed for the extensive identification and screening of oral bacterial pathogens and human papillomavirus (HPV) nucleic acids, making it appropriate for use in point-of-care environments. Thus, strong research and development for the advancement of CRISPR technology is expected to drive the market growth of infectious disease CRISPR in the North American region.

The government's increasing funding to boost product developments in CRISPR technology for infectious diseases is expected to fuel market growth in the region. For instance, in June 2024, researchers at the University of Florida secured a grant of about USD 2.8 million from the National Institutes of Health (NIH) to create an easy-to-use HIV detection test kit for home use, utilizing innovative CRISPR technology. This new CRISPR-based kit was designed to measure human immunodeficiency virus (HIV) RNA levels in patients through a compact microfluidic device, enabling individuals to quickly assess their status following potential exposure and can provide test results in a few minutes. Moreover, in April 2024, researchers at Washington University School of Medicine were funded with a USD 6.2 million grant from the National Institutes of Health (NIH) to create a gene therapy to alter the immune system's B cells to enhance their production of broadly neutralizing antibodies against HIV in which the viral vector can incorporate genes that encode the CRISPR/Cas9 gene-editing proteins. Thus, the rising investments by the government to boost research and development in CRISPR-based diagnostics and therapeutics are anticipated to drive market growth over the forecast period.

Moreover, the research institutes and academics are highly focused on developing advanced CRISPR-based diagnostics and treatments for infectious diseases to combat pandemics, thus expected to fuel the market growth in the region. For instance, in May 2024, researchers at the University of Alberta were set to assist Canada in preparing for future infectious disease pandemics, aided by nearly USD 75 million (CAD 100) million in new federal research grants aimed at developing vaccines, diagnostic tests, and treatments for various diseases. The team intended to utilize advanced tools, such as sequencing technologies to enhance the characterization of nucleic acids and proteins in pathogens, and CRISPR gene editing methods to create more targeted, accurate, and user-friendly point-of-care diagnostic tests. Thus, the increasing funding to develop CRISPR-based diagnostics and treatment approaches are likely to drive the market growth.

Therefore, owing to the above-mentioned factors, such as the increasing advancements in CRISPR technology and rising government investments in research and development, it is anticipated to contribute to the market growth in the region over the forecast period.

Infectious Disease CRISPR Industry Overview

The infectious disease CRISPR market is considered consolidated due to the significant number of dominant market players. Numerous companies and research organizations are engaged in developing CRISPR-based approaches for the diagnosis, treatment, and prevention of infectious diseases, resulting in a varied competitive environment. Key market players include Mammoth Biosciences, Inc., Sherlock Biosciences, Intellia Therapeutics, Inc., Thermo Fisher Scientific Inc. and Merck KGaA, among others.

Infectious Disease CRISPR Market Leaders

Infectious Disease CRISPR Market News

• August 2024: Locus Biosciences, Inc. presented positive findings from phase 1/2 trial ELIMINATE trial, which involves the assessment of LBP-EC01, a CRISPR-Cas3 genetically modified bacteriophage treatment aimed at patients suffering from uncomplicated urinary tract infections (uUTIs) due to antimicrobial-resistant (AMR) and multi-drug-resistant (MDR) Escherichia coli (E. coli). The primary and secondary outcomes of Part 1 were achieved, and an effective dosing regimen was established that demonstrated good tolerance and resulted in high drug levels at the site of infection among patients with uncomplicated urinary tract infections.
• May 2024: Excision BioTherapeutics' EBT-101 phase 1/2 trial successfully achieved its primary safety endpoint, as well as its secondary endpoints related to biodistribution and immunogenicity, demonstrating that the CRISPR-based gene editing therapy can be safely administered to target Human Immunodeficiency Virus (HIV) DNA reservoirs within human cells.